Skip to main content

Table 3 Predictors of response for patients with HCV genotype 1 infection

From: Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort

 

SVR 12

Relapse

p value

 

total: 74 % (56)

total: 26 % (20)

 

Age <65 years

95 % (53)

85 % (17)

0.1698

Age ≥65 years

5 % (3)

15 % (3)

Female

34 % (19)

20 % (4)

0.2445

Male

66 % (37)

80 % (16)

Non-cirrhotic

64 % (36)

35 % (7)

0.0233

Cirrhotic

36 % (20)

65 % (13)

Treatment naive

52 % (29)

45 % (9)

0.6024

Treatment experienced

48 % (27)

55 % (11)

HCV-RNA <6 (10E6 IU ml-1) at baseline

79 % (44)

85 % (17)

0.5352

HCV-RNA ≥6 (10E6 IU ml-1) at baseline

21 % (12)

15 % (3)

HCV-RNA <12 (IU ml-1) after 4 weeks of treatment

70 % (39)

35 % (7)

0.0065

HCV-RNA ≥12 (IU ml-1) after 4 weeks of treatment

30 % (17)

65 % (13)

Platelets <100 (10E3 μl-1) at baseline

18 % (10)

30 % (6)

0.2529

Platelets ≥100 (10E3 μl-1) at baseline

82 % (46)

70 % (14)

  1. Data are expressed as percent (number)
  2. SVR 12 sustained virological response at 12 weeks after end of treatment
  3. Boldface data statistically significant